Published in Curr Oral Health Rep on March 12, 2016
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst (1998) 5.05
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res (2000) 3.47
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res (2003) 3.09
Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol (2010) 3.02
Whole body irradiation; radiobiology or medicine? Br J Radiol (1953) 2.80
Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res (1999) 2.70
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res (2007) 2.57
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol (2013) 2.29
DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer (2008) 2.23
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
Role of macrophages in tumour progression. Immunol Lett (2009) 2.07
Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res (2002) 2.05
Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol (2008) 1.89
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.85
Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer (2005) 1.69
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res (2005) 1.48
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res (2006) 1.45
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol (2015) 1.45
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol (2013) 1.42
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol (2012) 1.27
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer (2012) 1.27
Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol (2014) 1.26
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol (2008) 1.23
Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol (2005) 1.21
Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol (2011) 1.15
TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl (1993) 1.13
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther (2007) 1.12
Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res (2012) 1.11
CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res (2015) 1.11
Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol Ther (2010) 1.08
Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck (2002) 1.06
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol (2011) 1.04
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med (2009) 1.03
A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer (2012) 1.02
Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) (2011) 1.01
Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. Adv Exp Med Biol (1998) 0.97
A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology (2015) 0.96
Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data. Oral Oncol (2014) 0.96
Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res (2012) 0.94
Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology (2001) 0.93
Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol (2013) 0.93
Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res (2014) 0.92
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer (2014) 0.92
Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope (1999) 0.89
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck (2014) 0.89
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck (2011) 0.88
Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol (2014) 0.88
Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg (2005) 0.87
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother (2011) 0.87
Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res (1993) 0.86
Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer (1993) 0.86
Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer (2002) 0.85
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer (2013) 0.83
IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients. Cancer Immunol Immunother (2012) 0.83
Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. Oncoimmunology (2015) 0.83
Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83
Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck (2015) 0.82
Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg (1990) 0.81
IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. PLoS One (2013) 0.81
Encouraging Results for Pembrolizumab in Head and Neck Cancer. Am Health Drug Benefits (2015) 0.81
Therapeutic cancer vaccines. Adv Cancer Res (2014) 0.79
Immunotherapy for head and neck squamous cell carcinoma. Oral Oncol (2015) 0.78
Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol Ther (2015) 0.77
Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol (2015) 0.77
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Invest New Drugs (2015) 0.77